Table 1. Demographic and clinical characteristics of patients.
| %/Median (Range) | |
|---|---|
| Age (years) | 63 (45–4) |
| BMI | 31.6 (20.7–51.4) |
| Average follow-up time (months) | 21.8 (1.2–233.1) |
| CA 125 | 21.07 (2.98–3290) |
| Tumor diameter (cm) | 6 (1–30) |
| Stage | |
| Stage 1 | 43.9 |
| Stage 2 | 14.3 |
| Stage 3 | 19.4 |
| Stage 4 | 12.4 |
| Lymphadenectomy | |
| Yes | 88.8 |
| No | 11.2 |
| Lymph node metastasis | |
| Yes | 22.4 |
| No | 66.3 |
| Residual disease (cm) | |
| >1 | 18.4 |
| <1 | 81.6 |
| Epithelial component | |
| Endometrioid type | 45.9 |
| Grade 1 | 2.0 |
| Grade 2 | 23.5 |
| Grade 3 | 20.4 |
| Non-endometrioid | 54.1 |
| Serous carcinoma | 44.9 |
| Squamous cell carcinoma | 4.1 |
| Undifferentiated carcinoma | 3.1 |
| Clear cell carcinoma | 1.0 |
| Serous + clear cell carcinoma | 1.0 |
| Mesenchymal component | |
| Homologous | 74.5 |
| Endometrial stromal sarcoma | 4.1 |
| Leiomyosarcoma | 14.3 |
| High-grade/differentiated sarcoma | 56.1 |
| Heterologous | 25.5 |
| Rhabdomyosarcoma | 13.3 |
| Chondrosarcoma | 8.2 |
| Osteosarcoma | 1.0 |
| Rhabdomyosarcoma/chondrosarcoma /osteosarcoma | 2.1 |
| Rhabdomyosarcoma/chondrosarcoma | 1.0 |
BMI (kg/m2): body mass index; CA 125 (IU/mL): cancer antigen 125.